Halozyme Therapeutics Inc (HALO) Return on Equity ROE from the second quarter 2026 to second quarter 2025 and annually, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Halozyme Therapeutics Inc   (NASDAQ: HALO)

Halozyme Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Halozyme Therapeutics Inc in the second quarter 2026?
Halozyme Therapeutics Inc achieved a return on average equity (ROE) of 180.63 % in its second quarter 2026, this is above HALO's average return on equity of -59.26%.
Halozyme Therapeutics Inc shareholder's equity over the 12 months ending in its second quarter 2026 are valued at $229 million

ROE has advanced compared to 126.27% in the first quarter 2026, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry only one company had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 71, from total ROE ranking in the first quarter 2026 at 72.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Equity Change -56.86 % -54.46 % -86.58 % 11.31 % -
Y / Y Net Income Change 39.21 % 27.06 % - 27.89 % 77.12 %
Net Income (TTM) in Millions 414 349 317 595 557
Return On Equity (TTM) 180.63 % 126.27 % 92.67 % 141.55 % 136.63 %
HALO's Total Ranking # 71 # 72 # 21 # 40 # 23
Equity (TTM) in Millions 144 220 49 504 333
Seq. Equity Change -34.65 % 349.94 % -90.31 % 51.44 % -31 %
Seq. Net Income Change 53.23 % - - 6.09 % 39.85 %

Back to HALO Management Effectiveness >> HALO's 5 Years Annual ROE >> Compare HALO ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 2
Sector # 9
Overall # 71

Return On Equity Statistics
High Average Low
263.91 %
-59.26 %
-1725.85 %
(Sep 30 2021)   (Dec 31 2013)





HALO Annual Return On Equity (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Equity in Millions 49 364 84 170 197
Y / Y Equity Change -86.58 % 334.11 % -50.64 % -13.79 % 30.39 %
Net Income in Millions 317 444 282 202 403
Y / Y Net Income Change -28.64 % 57.71 % 39.31 % -49.81 % 211.97 %
Return On Equity 649.18 % 122.06 % 336 % 119.04 % 204.47 %

Back to HALO Management Effectiveness >> HALO's 5 Years Annual ROE >> Compare HALO ROE to its Competitors




Annual Roe Comment
Despite deterioration in net income, company improved ROE to in 2025, company improved ROE to 649.18 % compared to the prior year.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
HALO's' Return on Equity at Yahoo Finance
HALO's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for HALO's Competitors
Subscribers only: Roe for Halozyme Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for HALO's Customers




Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector ROE
Meiragtx Holdings Plc  283.67 %
Silexion Therapeutics Corp  276.59 %
Actinium Pharmaceuticals Inc  213.46 %
Halozyme Therapeutics Inc   180.63 %
Capforce Inc   168.50 %
Aveanna Healthcare Holdings Inc   150.35 %
Liquidia Corporation  149.64 %
Interpace Biosciences Inc   142.98 %
Oncotelic Therapeutics Inc   124.17 %
Fortress Biotech Inc   118.22 %
Medpace Holdings Inc   110.15 %
Pulmatrix Inc   108.83 %
Rigel Pharmaceuticals Inc  96.49 %
Exelixis Inc   93.62 %
Alnylam Pharmaceuticals Inc   93.61 %
Eli Lilly And Company  92.54 %
Arbutus Biopharma Corp  90.98 %
Amgen Inc   89.32 %
Q32 Bio Inc   76.88 %
3m Company  76.55 %
Oramed Pharmaceuticals Inc  73.03 %
Tg Therapeutics Inc   72.30 %
Idexx Laboratories Inc  71.96 %
Elite Pharmaceuticals Inc   71.10 %
Zoetis Inc   68.87 %
Rallybio Corporation  68.56 %
Earth Science Tech Inc   66.17 %
Aurinia Pharmaceuticals Inc   59.00 %
Vaxart Inc   53.04 %
Qhslab Inc   51.21 %

Date modified: 2026-09-12T06:14:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.